8 Recruiting Hairy Cell Leukemia Clinical Trials in Maryland
Explore active hairy cell leukemia research studies enrolling across Maryland. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Hairy Cell Leukemia Studies in Maryland
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
📍 NCI - Center for Cancer Research — Bethesda, Maryland
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔